Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy

OBJECTIVE: Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19. DESIGN AND METHODS: Prospective, obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagi, Filippo, Trevisan, Sasha, Piccica, Matteo, Graziani, Lucia, Basile, Gregorio, Mencarini, Jessica, Borchi, Beatrice, Menicacci, Lorenzo, Vaudo, Micol, Scotti, Valentina, Fabbri, Alessia, Bandini, Giulia, Tozzetti, Camilla, Berni, Andrea, Aiezza, Noemi, Pestelli, Giulia, Turchi, Valerio, Pignone, Alberto Moggi, Poggesi, Loredana, Nozzoli, Carlo, Morettini, Alessandro, Rossolini, Gian Maria, Bartoloni, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064815/
https://www.ncbi.nlm.nih.gov/pubmed/33901656
http://dx.doi.org/10.1016/j.ijid.2021.04.065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064815/
https://www.ncbi.nlm.nih.gov/pubmed/33901656
http://dx.doi.org/10.1016/j.ijid.2021.04.065

Ejemplares similares